biosimilars Europe
Fourth Humira biosimilar set for EU approval
Dominic Tyer
AbbVie, adalimumab, biosimilars, biosimilars Europe, CHMP, Humira, Novartis, Sandoz
0 Comment
EC to update IP rules to benefit generic exports
Linda Banks
biosimilar, biosimilars Europe, EC, EU, European Commission, European pharma, generics, pharma IP, Pharma regulation
0 Comment
The European Commission (EC) is proposing to adjust intellectual property (IP) rules to help Europe’s pharma companies tap into fast-growing global markets.
Articles/ Healthcare/ Pharma Market Access/ UK & Europe/ Views and analysis
3 Questions on biosimilars in Europe: Adrian van den Hoven
Andrew McConaghie
biosimilars, biosimilars Europe, cancer biosimilars, Medicines for Europe
0 Comment
Adrian van den Hoven of Medicines for Europe addresses three big questions facing the biosmilars sector in Europe in 2018.